Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
10.2.2017

Supreme Court Denies J&J’s Petition in Ethicon Sling MDL

October 2, 2017

The U.S. Supreme Court has denied Johnson & Johnson’s petition for a writ of certiorari, ending their appeal of a $3.27 million bellwether trial verdict in the case of Jo Huskey, et al. v. Ethicon, Inc., et al.

The U.S. Supreme Court on Oct. 2 declined to review  the Fourth Circuit’s affirmation of the federal district court’s exclusion of evidence relating to a pelvic mesh device’s market clearance through the less-stringent 510(k)review  process because that clearance process does not constitute a formal review of the device’s  safety and efficacy by the Food and Drug Administration (“FDA”).

Plaintiffs’ in this case are represented by Edward A. Wallace and Mark R. Miller of Wexler Wallace LLP; Fidelma L. Fitzpatrick of Motley Rice LLC; and Thomas P. Cartmell and Jeffrey M. Kuntz of Wagstaff & Cartmell LLP.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP